Joshua Fitch, Senior Editor

Donna Hallas, PhD, CPNP, PPCNP-BC, PMHS, FAANP, FAAN, believes behavioral health is currently at the forefront of pediatric health care and explains how simple questions can lead to better care for a child.

According to the data, vaccination coverage in the United States has been lower in this influenza season compared to the previous season and to seasons before the COVID-19 pandemic.

The device is intended for anyone aged 18 years and up who do not use insulin or those without diabetes who want to learn how diet can impact blood sugar levels.

Scott Ceresnak, MD, explains ways AI technology could be useful when it comes to pediatric cardiology, though he states "big" research data is needed to generate pediatric specific algorithms.

The federal agency approved Perflutren Lipid Microsphere following positive data from 3 pediatric clinical trials.

Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

Guidance now aligns with isolation recommendations for influenza and other respiratory illnesses.

Across all age groups polled, 49% of parents agreed that using headphones helped keep their child entertained.

Study authors of a paper published in The New England Journal of Medicine highlighting omalizumab for multiple common food allergies provided their comments regarding positive phase 3 data.

Scott Ceresnak, MD, explains smartwatch technology could be a great tool in detecting arrhythmias in children, however, given that algorithms in the technology were designed for adults, caution must be used as well.

"Collaboration can help us make more accurate diagnoses, develop more effective multimodal treatment plans, and monitor progress in many areas," said James Wallace, MD.

A poster presentation at AAAAI from the phase 3 PEOPLE Study revealed DBV712 treatment in children with peanut allergy has a favorable safety and tolerability profile.

Omalizumab was approved by the FDA on February 16, 2024 as the first and only FDA-approved medicine to reduce allergic reactions in patients with 1 or more food allergies.

Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

Thomas Casale, MD, discusses phase 3 data presented at the 2024 AAAAI Meeting in Washington DC, highlighting neffy's efficacy in pediatric patients at risk for anaphylaxis.

Sarina Tanimoto, MD, MBA, breaks down a poster session regarding the pharmacokinetic profile of neffy, presented at the 2024 American Academy of Allergy, Asthma, & Immunology Annual Meeting in Washington DC from February 23 to February 26, 2024.

The Rare Pediatric Disease Designation joins the Fast Track and Orphan Designations that have already been granted to AOC 1044.

A Prescription Drug User Fee Act (PDUFA) target action date of June 21, 2024, has been set by the FDA.

ARS Pharma plans to submit data from the repeat dose study of neffy to the FDA early in the second quarter of 2024, as part of its response to the CRL issued by the federal agency for the previously submitted New Drug Application (NDA).

How effective can wearable technology with features designed for adults be for children when it comes to arrhythmias? Scott Ceresnak, MD, helps provide the answer in this Contemporary Pediatrics interview.

Procalcitonin can be useful for point-of-care testing in patients with influenza-like illness and a prolonged fever, guiding the indication for a chest radiograph while helping to avoid radiation exposure.

Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

The approval makes omalizumab the first and only FDA-approved medicine to reduce allergic reactions in patients with one or more food allergies.

The Orphan Drug Designation follows the receipt of Rare Pediatric Disease Designation from the FDA in January 2024.

Lawrence Eichenfield, MD, highlights the sNDA submission of tapinarof cream, 1% for the topical treatment of atopic dermatitis in children aged 2 years and older.

Promoting mental health and implementing stress-reducing scenarios for adolescents could lessen motivating factors for substance use.

Results demonstrated that foster care involvement does vary based on age and sex, with Black youths and females disproportionately effected.

The sNDA submission follows additional positive topline data that was presented in Janurary 2024, highlighting an open-label, long-term extension study evaluating tapinarof cream, 1%.

Compared to children with no maternal tobacco usage during pregnancy, those exposed had associations to childhood neurocognition deficits.

Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.